<SEC-DOCUMENT>0001513162-21-000004.txt : 20210114
<SEC-HEADER>0001513162-21-000004.hdr.sgml : 20210114
<ACCEPTANCE-DATETIME>20210113192541
ACCESSION NUMBER:		0001513162-21-000004
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210112
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210114
DATE AS OF CHANGE:		20210113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		21527154

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8k.htm
<DESCRIPTION>FORM_8K
<TEXT>
<HTML>
<head><title>Form 8k</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b>UNITED STATES</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b>SECURITIES AND EXCHANGE COMMISSION</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b>WASHINGTON, D.C.</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b>FORM 8-K</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b>CURRENT REPORT</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Pursuant to Section 13 or 15(d) of the</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Securities Exchange Act of 1934</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Date of Report (date of earliest event reported): <b>January 12, 2021</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>BIOMERICA, INC.</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Exact Name of Registrant as Specified in its Charter)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <div align=center> <table width=696 bordercolor=transparent style="WIDTH:7.25in; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style=COLOR:black>Delaware</font></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style=COLOR:black>001-37863</font></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style=COLOR:black>95-2645573</font></p></td></tr> <tr style=HEIGHT:26pt> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(State or Other Jurisdiction</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>of Incorporation)</p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(Commission</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>File Number)</p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(IRS Employer</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>Identification Number)</p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>17571 Von Karman Ave.</p> <h1 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif";  FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0in 0pt'>Irvine, California 92614</h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Address of Principal Executive Offices</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Zip Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>949-645-2111</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Registrant&#146;s Telephone Number,</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Area Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b>Not applicable</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Former Name or Former Address if Changed</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Since Last Report)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt 0in 0pt'>&#61608;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font face=Wingdings>o</font>&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:Times New Roman New,Times New Roman; PADDING-LEFT:174px;MARGIN:0px; TEXT-INDENT:-2px" align=justify>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&#61608;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font face=Wingdings>o</font>&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&#61608;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font face=Wingdings>o</font>&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:Times New Roman New,Times New Roman; PADDING-LEFT:174px;MARGIN:0px; TEXT-INDENT:-2px" align=justify>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&#61608;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font face=Wingdings>o</font>&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:3pt 0in 0pt; LINE-HEIGHT:120%'>Securities registered pursuant to Section 12(b) of the Act:</p> <div align=center> <table width=683 bordercolor=transparent style="WIDTH:512pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif";  TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Title of each class</font></u></b></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif";  TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Trading Symbol</font></u></b></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif";  TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif";  TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">Common Stock, par value $0.08</font></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif";  TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">BMRA</font></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif";  TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in -10pt 0pt 0in; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in -10pt 0pt 0in; LINE-HEIGHT:120%'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font> </p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt -10pt 0pt 0in; LINE-HEIGHT:120%'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b>Item 7.01 Regulation FD Disclosures.</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:2.9pt'>On January 12, 2021, Biomerica, Inc. (&#147;Biomerica&#148;) issued a press release announcing the Company has received the CE Mark for its new <a name=_Hlk60998831>COVID-19 Rapid Antigen Test </a>for detection of COVID-19 infection. The Company also announced it has already received its first European orders and plans to ship the first part of these orders in the coming weeks. </p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:2.9pt'>A copy of Biomerica&#146;s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of, or otherwise regarded as filed under, the&nbsp;Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b>Item 8.01&nbsp; Other Events.</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>On January 8, 2021, the Company received the CE mark for its COVID-19 Rapid Antigen Test for detection of COVID-19 infection.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style=COLOR:black>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.25in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>&nbsp;</p> <div align=center>  <table width=80% bordercolor=transparent style="WIDTH:80%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=9% nowrap style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%' align=center><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">&nbsp;</font><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">Number</font></u></b></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">&nbsp;&nbsp;</font></p></td> <td width=89% nowrap style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.7pt; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">Description</font></u></b></p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%' align=center>99.1</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in -5.65pt 0pt 0in; LINE-HEIGHT:115%'>Press Release issued January 12, 2021.</p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif";  FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0.3in 0pt 0in'>SIGNATURE</h2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0.3in 0pt 0in'>&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 7pt 275pt; TEXT-INDENT:-23pt'><a name=Form_8_K />&nbsp;</p> <table width=600 bordercolor=transparent style="WIDTH:6.25in; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=359 style="HEIGHT:14pt; WIDTH:269pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'>&nbsp;</p></td> <td width=337 colspan=3 style="HEIGHT:14pt; WIDTH:253pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'><font style=COLOR:black>Biomerica, Inc.</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=359 style="HEIGHT:15pt; WIDTH:269pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'>&nbsp;</p></td> <td width=32 style="HEIGHT:15pt; WIDTH:24pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'>&nbsp;</p></td> <td width=15 style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'>&nbsp;</p></td> <td width=291 style="HEIGHT:15pt; WIDTH:218pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=359 style="HEIGHT:15pt; WIDTH:269pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'><font style=COLOR:black>Dated:&nbsp; January 14, 2021</font></p></td> <td width=32 style="HEIGHT:15pt; WIDTH:24pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'><font style=COLOR:black>By:</font></p></td> <td width=15 style="HEIGHT:15pt; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'>&nbsp;</p></td> <td width=291 style="BORDER-LEFT-WIDTH:medium; HEIGHT:15pt; BORDER-RIGHT-WIDTH:medium; BORDER-TOP-COLOR:; WIDTH:218pt; BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT-COLOR:; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-RIGHT-COLOR:; PADDING-RIGHT:2pt; BORDER-TOP-WIDTH:medium" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in; break-after:avoid'><font style=COLOR:black>/s/ Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:0.6in> <td width=359 style="HEIGHT:0.6in; WIDTH:269pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'>&nbsp;</p></td> <td width=32 style="HEIGHT:0.6in; WIDTH:24pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'>&nbsp;</p></td> <td width=15 style="HEIGHT:0.6in; WIDTH:11pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'>&nbsp;</p></td> <td width=291 style="HEIGHT:0.6in; WIDTH:218pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'><font style=COLOR:black>Zackary S. Irani<br>Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></div></body>
<!-- EDGAR Validation Code: ED5ADE01 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>Exhibit99_1.htm
<DESCRIPTION>EXHIBIT99_1
<TEXT>
<HTML>
<head><title>exhibit 99.1</title> </head> <body vlink=purple link=blue lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; MARGIN:0in 0in 0pt'><b><font style=COLOR:red>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; MARGIN:0in 0in 0pt' align=center><img width=997 height=92 style="HEIGHT:71px; WIDTH:1130px" src=logo.jpg></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; MARGIN:0in 0in 0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"USABlack","sans-serif"; COLOR:black; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=left><b><font style='FONT-FAMILY:"Verdana","sans-serif"; COLOR:#464646'><br></font></b><b><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; TEXT-TRANSFORM:uppercase; COLOR:#002c40" face="Times New Roman">Biomerica&#146;S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark </font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"USABlack","sans-serif"; COLOR:black; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=left><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"USABlack","sans-serif"; COLOR:black; TEXT-ALIGN:left; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.25in' align=left><font face="Times New Roman"><font style="FONT-SIZE:12.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:12.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica receives first orders and plans to ship tests in coming weeks </font></b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"USABlack","sans-serif"; COLOR:black; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=left><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"USABlack","sans-serif"; COLOR:black; TEXT-ALIGN:left; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.25in' align=left><font face="Times New Roman"><font style="FONT-SIZE:12.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:12.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement (specificity) as compared to lab-based molecular PCR tests</font></b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"USABlack","sans-serif"; COLOR:black; TEXT-ALIGN:left; MARGIN:0in 0in 0pt' align=left><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial Unicode MS","sans-serif"; COLOR:#333333; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:2.9pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><font face="Times New Roman">IRVINE, California, January 12, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it has received CE Mark for its new </font><a name=_Hlk60998831><font face="Times New Roman">COVID-19 Rapid Antigen Test </font></a><font face="Times New Roman">for detection of COVID-19 infection. The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. The Company will now begin marketing this product broadly in Europe and other regions outside of the US. &nbsp;</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial Unicode MS","sans-serif"; COLOR:#333333; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:2.9pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><font face="Times New Roman">Biomerica&#146;s new COVID-19 Antigen Rapid Test is highly portable, affordable, and provides results in 15 minutes with no equipment required to perform or read the test. Because this test can be performed by doctors, nurses, school nurses, and medical assistants, the </font><a name=_Hlk61002355><font face="Times New Roman">Biomerica </font></a><a name=_Hlk61006749><font face="Times New Roman">COVID-19 Rapid Antigen Test </font></a><font face="Times New Roman">can be performed at the point of care, outside of medical labs, taking pressure off of labs performing COVID-19 testing.&nbsp; The test also provides results in 15 minutes versus lab-run PCR tests which can take up to three days for results, thereby potentially expediting the process of identifying infectious people so they don't spread the disease to others.</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial Unicode MS","sans-serif"; COLOR:#333333; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:2.9pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><font face="Times New Roman">About the Biomerica COVID-19 Rapid Antigen Test: The Biomerica COVID-19 Rapid Antigen Test is intended to identify people who are currently infected and who should quarantine to help prevent the spread of the disease. No lab equipment is necessary to process the test or read the tests results. This test uses lateral flow technology, making it a reliable and familiar format for mass testing by healthcare providers. In independent testing at clinics in three different countries outside of the US, the Biomerica COVID-19 Rapid Antigen Test demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement (specificity) as compared to lab-based molecular PCR tests.&nbsp; The Biomerica COVID-19 Rapid Antigen Test was engineered for near-patient, point-of-care settings. A simple nasal swab is used to collect specimens from people suspected of having an active infection. Patient samples should be tested immediately and should not be diluted or used with viral transport media or frozen specimens. </font><a name=_Hlk60910035 /></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial Unicode MS","sans-serif"; COLOR:#333333; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:2.9pt'><font face="Times New Roman"><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">&#147;We are pleased to launch the Biomerica COVID-19 Rapid Antigen Test to help combat this ongoing global pandemic and which may help people become more confident about their own health,</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">&#148; said Zack Irani, CEO at Biomerica. &nbsp;</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">&#147;While we are proud to be contributing to the management of the current global pandemic and help bring more normalcy into our lives, our primary focus remains the validation and commercialization of products that are based on our patented InFoods&#174; technology platform. We continue to believe our InFoods&#174; products could revolutionize the way people are diagnosed and treated for a variety of common diseases including Irritable Bowel Syndrome (IBS). As such, we see a large potential for helping the millions of patients suffering with IBS,&#148; he concluded.</font></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:14pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">About Biomerica (NASDAQ: BMRA)</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica, Inc. (</font><font face="Times New Roman"><font style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; COLOR:windowtext'><font style="FONT-SIZE:10.5pt; TEXT-DECORATION:none; FONT-FAMILY:Avenir; COLOR:#0071bb">www.biomerica.com</font></font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica&#146;s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. </font></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><font size=+0>&nbsp;</font></font></p> <div style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><font size=+0> <hr> <div style=PAGE-BREAK-BEFORE:always>&nbsp;</div> </font></font></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; MARGIN:0in 0in 0pt' align=center><img width=997 height=92 style="HEIGHT:71px; WIDTH:1130px" src=logo.jpg></p><p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b></b>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">About InFoods&#174; </font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">The Biomerica InFoods&#174; IBS product is designed to allow physicians to identify patient-specific foods (e.g., eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient-specific, guided dietary regimen to improve IBS outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product is expected to be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods&#174; diagnostic products. Since the InFoods&#174; product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits. </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company&#146;s COVID-19 tests, FDA clearance, EUA clearance, the rapidity of testing results, uniqueness of a product, accuracy of products, &nbsp;pricing of the Company&#146;s test kits, demand for international orders, availability of the Company&#146;s COVID-19 test kits, and patent protection on the test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation:&nbsp; results of studies testing the efficacy of the Company&#146;s COVID-19 tests; regulatory approvals necessary prior to commercialization of the Company&#146;s COVID-19 tests; availability of the Company&#146;s COVID-19 test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various COVID-19 tests; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company&#146;s ability to obtain patent protection on any aspects of its rapid test technology. &nbsp;Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Corporate Contact: </font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Company Spokeperson</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">949-645-2111</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p></div></body>
<!-- EDGAR Validation Code: CCBFD833 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !< ^0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ'&3_OJ;_P"*KT3X(?">]^%UA>IJ&JOJL]U(&5RSD(H'3YB>]>=?\('\:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
